December 2015

25 December 2015

Require M.Pharm/M.Sc as Project Fellow for tuberculosis research

Applications are invited from Indian nationals for the project No: TCOF 22 “Synthesis of thiazole based compounds for antitubercular screening” for a period of six months and will be extended for another six months subject to review.

Post: Project Fellow

25 December 2015

Applications are invited for the post of JRF at NSHM

NSHM Knowledge Campus is all about experiential learning and building an ever-expanding knowledge base involving knowledge partners and communities. NSHM is where information and ideas flow freely in an open and friendly atmosphere – a “Knowledge Hub of Global Excellence” in which students learn, share, shine and have fun.

25 December 2015

Vacancies in pharmaceutical sales at Johnson & Johnson - freshers may apply

Caring for the world, one person at a time... inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Employees of the Johnson & Johnson Family of Companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

25 December 2015

Career for Pharmacists (3 posts) at National Health Mission

Applications are invited for filling up vacant positions under National Health Mission & rural health mission

Post: Pharmacist

Read more about How 'self-sabotage' prevents immune response against malaria

New research has revealed how malaria parasites cause an inflammatory reaction that sabotages our body's ability to protect itself against the disease.

Read more about Environmental pollution too behind antibiotic resistance?

Can the emergence of antibiotic-resistant bacteria be squarely blamed on the misuse and overuse of antibiotics? No, there is more to the problem than the misuse of common medications, says a University of Georgia researcher.

Read more about Merck’s investigational Ebola vaccine for Emergency Use Assessment and Listing accepted for review by WHO

Merck, known as MSD outside the United States and Canada, announced that the application for Emergency Use Assessment and Listing (EUAL) for the company’s investigational Ebola Zaire vaccine, V920 (rVSV?G-ZEBOV-GP, live attenuated), has been accepted for review by the World Health Organization (WHO).

Read more about Oral REVLIMID® Plus Dexamethasone Granted Approval for Treatment of Patients with Newly Diagnosed Multiple Myeloma in Japan

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation announced that REVLIMID® (lenalidomide), a cancer medicine that is administered orally, has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for use in combination with dexamethasone as a treatment for patients newly diagnosed with multiple myeloma. This marketing authorization expands upon the approval of REVLIMID in 2010 for the treatment of patients with relapsed or refractory multiple myeloma.

Read more about Recipharm collaborate with Alcon & acquires facility in France

Recipharm AB, a leading contract development and manufacturing organisation in the pharmaceutical industry, has entered into the previously announced strategic collaboration with Alcon, a Novartis company, and signed a long term supply agreement whereby Recipharm will manufacture a range of ophthalmic products using Blow Fill Seal technology.

Read more about Sanofi get Philippines approval to market dengue vaccine

Sanofi Pasteur, the vaccines division of Sanofi, announced that the Philippines have granted marketing approval to Dengvaxia®, making it the first vaccine to be licensed for the prevention of dengue in Asia.